anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To pilot a trial assessing the safety and pharmacokinetics (PK) of perioperative IV L-carnitine administration in these patients. To this end, a pilot clinical trial is proposed. Infants with VSD or AVSD undergoing complete repair will receive L-carnitine, in one of 3 doses (25, 50, or 100 mg/kg, IV), just prior to CPB, and again 2 hr after CPB. Serial blood samples will be obtained to determine free, total, and acylcarnitine levels, and plasma markers of mitochondrial function, oxidative stress, and bioavailable NO. Adverse events will be sought, and clinical outcomes will be assessed.

Study design: The inclusion and exclusion criteria are as described in Aim 3A except only infants with VSD or AVSD will be enrolled (no TOF). The safety profile of L-carnitine is outstanding, with no reports of toxicity from overdose reported113. In fact, the only adverse reactions reported are transient nausea and vomiting, and less commonly gastritis. However, although rare, seizures have been reported to occur in patients receiving L-carnitine. Therefore, the major adverse events that will be monitored include evidence of seizure activity and GI bleeding. As per routine, any patient suspected of having seizures is monitored with continuous EEG. Dosing is not well studied in children, particularly critically ill children67, 114-116117. In addition, the effect of CPB on L-carnitine clearance in children is not known. Therefore, a major goal of this sub-aim is to establish a pharmacokinetic profile of L-carnitine in this patient population undergoing surgery with CPB, in order to move forward with a larger randomized trial powered for efficacy in prevention of increased PVR post-bypass in at-risk infants. Plasma concentration profiles after IV bolus dosing in adults were described by a two-compartmental model67, 113, 114, 118. Usual pediatric dosing is not well delineated, but recommendations include a 50 mg/kg bolus followed by an infusion of 50mg/kg/day, that can be increased to 300 mg/kg/day113, 119. Therefore, we will begin at a lower dose (25 mg/kg), and escalate the dose after each group of 5. No intra-patient escalation will be allowed and the dose will not be escalated until all patients in the current dose level have been followed to hospital discharge or 30 days post-op and the safety and PK data have been analyzed. The DSMB will approve all dose escalations. The dosing goal will be to achieve normal or supra-normal free carnitine levels (\~50 μmol/L) and low AC levels (\~3 μmol/L) just before and for 24 hrs after CPB; the period with the greatest risk of pulmonary vascular morbidity.
Cross-sectional studies indicate that menstrual problems are related to poorer mental health; however, longitudinal studies are limited. This longitudinal study aimed to determine whether baseline menstrual characteristics were risk factors for incident and persistent mental health problems. The study was conducted among Chinese adolescent girls. Menstrual characteristics including menarche, menstrual cycle and menstrual pain were assessed at baseline, whereas mental health problems including PTSD, depression, anxiety, ADHD, insomnia, psychotic-like experiences, non-suicidal self-injury, suicide ideation, suicide plan, and suicide attempt were assessed at baseline (n = 1039) and at the 1-year follow-up (n = 946) by self-administered, structured questionnaires. Multiple logistic regressions were performed to examine whether menstrual characteristics were associated with incident (e.g., PTSD at follow-up but not baseline) and persistent (e.g., PTSD at both time points) mental health problems. The results demonstrated that early menarche was related to persistence of psychotic-like experiences; irregular menstruation was associated with higher rates of incident anxiety and insomnia, and persistent depression, anxiety, ADHD, insomnia, non-suicidal self-injury, suicide ideation, and suicide plan; menstrual pain was associated with elevated rates of incident PTSD and depression, and persistent depression, insomnia, psychotic-like experiences, non-suicidal self-injury, suicidal ideation, suicide plan, and suicide attempt. In conclusion, irregular menstruation and menstrual pain specifically contributed to the development of emotional problems and insomnia, and were associated with maintenance of the most mental health problems in early adolescence. The long-term effects of menstrual problems on mental health need further study.
A medical device monitor (MedMon), method and computer readable medium is disclosed. The MedMon is configured to operate in a system having communications between a first medical device associated with a patient and a second device. The MedMon includes a receiver configured to snoop on communications between the first medical device and second device. An anomaly detector having a set of security polices is configured to detect an anomaly by analyzing the communications between the first medical device and second device for compliance with the security policies. A response generator configured to generate a response on a condition that an anomaly is detected. The response may be a warning message configured to warn the patient. The MedMon may include a transmitter configured to transmit the response. The response may be a jamming signal configured to disrupt communications between the first medical device and second device.
BACKGROUND: Direct oral anticoagulants (DOACs) have been the drug of choice for preventing ischemic stroke in patients with atrial fibrillation since 2014. In previous studies, the stroke risk while taking warfarin was 2 per 100 patient-years and 1.5% per year while taking DOACs. We hypothesized that even if ischemic stroke occurred during anticoagulation therapy with DOACs, the prognosis was likely to be better than that with warfarin.
METHODS AND RESULTS: Data from 2002 to 2019, sourced from a nationwide claims database, were used to identify atrial fibrillation patients using International Classification of Diseases codes. Patients who experienced an ischemic stroke during anticoagulation were categorized by the drugs used (warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban). The primary outcome was mortality within 3 months and 1 year after the ischemic stroke. Among the 9578 patients with ischemic stroke during anticoagulation, 3343 received warfarin, and 6235 received DOACs (965 dabigatran, 2320 apixaban, 1702 rivaroxaban, 1248 edoxaban). The DOACs group demonstrated lower risks of 3-month (adjusted hazard ratio [HR], 0.550, [95% CI, 0.473-0.639]; P<0.0001) and 1-year mortality (adjusted HR, 0.596 [95% CI, 0.536-0.663]; P<0.0001) than the warfarin group. Apixaban and edoxaban within the DOAC group exhibited particularly reduced 1-year mortality risk compared with other DOACs (P<0.0001).
CONCLUSIONS: Our study confirmed that DOACs have a better prognosis than warfarin after ischemic stroke. The apixaban and edoxaban groups had a lower risk of death after ischemic stroke than the other DOAC groups.
An alert system usable to protect an individual from infectious disease is disclosed. The alert system can make use of one or more body-worn sensors to identify different entities within an environment, as well as their positional relationship (e.g., distance) to a reference location (e.g., the user and/or the alert system). The alert system can present alerts, such as through an augmented reality (AR) display, to identify potential risks and provide information to help minimize risk of infection. The AR display can identify risks with helpful and easy-to-interpret graphics or other overlays. Potential risks can include proximity to other individuals in an environment, contact with high-touch surfaces (e.g., fomites), insufficient cleaning (e.g., insufficient handwashing techniques), and others. The alert system can monitor the environment in real-time to assist the user in preventing transmission of pathogens to or from the user.
The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
PURPOSE:To economically obtain a sustained release pharmaceutical capable of surely controlling the elution of a drug without any influence of tableting pressure or hardness, by adding a water-soluble high polymer and a disintegrating agent which is another elution regulator to the drug and uniformly dispersing both components therein. CONSTITUTION:A sustained release pharmaceutical obtained by uniformly dispersing a water-soluble high polymer, e.g. hydroxypropyl methyl cellulose, polyvinylpyrrolidone (PVP) or polyvinyl alcohol (PVA), drug and a disintegrating agent, e.g. a mixture of microcrystalline cellulose with sodium carboxymethyl cellulose (CMC-Na), starch or CMC, therein and tableting the resultant mixture by a well-known method. Since a great variation in elution due to the little difference in amount of the water-soluble high polymer can be controlled by a controlling factor for accelerating the elution by the disintegrating agent which is another elution regulator, the elution of the drug can be surely controlled. Thereby, the aimed sustained release pharmaceutical can be simply and economically obtained.
Pilates is an exercise form created by Joseph Pilates in the 1920s. It is a programme of mind-body exercise focusing on strength, core stability, flexibility, muscle control, posture and breathing. Neuropilates is the practice of clinical pilates in patients with a neurological condition. The exercise is ideally led by a clinician with experience and expertise in the area and uses postural, positional and equipment adaptations as necessary to suit the needs of the client. The benefits derived from pilates exercise of balanced strength with improved alignment, postural control and flexibility, could be favourable to post stroke patients who often have one-sided loss of strength and muscle length and subsequent adverse postural adaptations and abnormal movement patterns.

This study aims to investigate the effects of a 6-week neuropilates class in post stroke patients, when compared with a 6-week generalised exercise class. Participants will be assessed before and after partaking in either class in order to examine their gait, functional independence and spasticity. Participants will then be randomly assigned to either the 6-week neuropilates class or generalised exercise class. Participants will be 6 or more months post stroke and finished their formal rehabilitation. Participants should not be involved with any other rehabilitation therapies / hydrotherapy / gym services for the duration of the study. We will aim to recruit 30 participants to the study. The intervention group will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor). The control group will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility. Both exercise classes will take place in the Physiotherapy Department in St. John's Hospital, Sligo, Ireland
NovoLog Mix 70/30 is an insulin analog with an earlier onset and intermediate duration of action in comparison to the basal human insulin premix. The addition of protamine to the rapid-acting aspart insulin analog (NovoLog) results in insulin activity that is 30% short-acting and 70% long-acting. NovoLog Mix 70/30 is typically dosed on a twice-daily basis (with each dose intended to cover 2 meals or a meal and a snack). The dosage of NovoLog Mix 70/30 must be individualized. The written prescription for NovoLog Mix 70/30 should include the full name, to avoid confusion with NovoLog (insulin aspart) and Novolin 70/30 (human premix).

NovoLog Mix 70/30 should appear uniformly white and cloudy. Do not use it if it looks clear or if it contains solid particles. NovoLog Mix 70/30 should not be used after the printed expiration date. 

NovoLog Mix 70/30 should be administered by subcutaneous injection in the abdominal region,  buttocks, thigh, or upper arm. NovoLog Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation. Injection sites should be rotated within the same region to reduce the risk of lipodystrophy. As with all insulins, the duration of action may vary according to the dose, injection site, blood flow, temperature, and level of physical activity.

NovoLog Mix 70/30 should not be administered intravenously or used in insulin infusion pumps. Dose regimens of NovoLog Mix 70/30 will vary among patients and should be determined by the health care professional familiar with the patient’s recommended glucose treatment goals, metabolic needs, eating habits, and other lifestyle variables.
Consumption of Brassica vegetables (which include broccoli, cabbage, and kale) is inversely associated with the incidence of several cancers, including cancers of the lung, stomach, liver, colon, rectum, breast, endometrium, and ovaries. Brassica vegetables are a good source of many nutrients, but the unique characteristic of Brassicas is their rich content of glucosinolates. Glucosinolates are sulfur-containing compounds that are converted to bioactive metabolites by a plant enzyme called myrosinase, which is released when the vesicles containing myrosinase are ruptured by chewing or cutting. These bioactive compounds are considered to be the active agent for cancer prevention. Their ability to reduce risk of cancer may derive in part from their ability to modulate foreign-substance metabolizing enzymes, which include enzymes called Phase I cytochrome P450s and Phase II enzymes.

The primary aim of this study is to investigate how daily consumption of kale influences foreign-substance metabolizing enzymes, which in turn may reduce cancer risk. Secondary aims of this study include measuring metabolism of kale nutrients, effect of kale consumption on fecal microbiota, and how kale consumption influences risk factors for cardiovascular disease.
Participants in both phase I and phase II portions receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
Maternal and/or perinatal death review or audits aim to improve the quality of health services and reduce deaths due to causes identified. A death review audit cycle identifies causes of deaths and possible modifiable factors, these can point to potential breaks in the continuity of health care and other health systems faults and challenges. It is an important function of audit cycles to develop, implement, monitor, and review action plans to improve the service. The WHO has produced two handbooks (Making Every Baby Count and Monitoring Emergency Obstetric Care) to guide maternal and perinatal death reviews. Health worker related factors accounts for two thirds of aspects that, if done differently may have prevented the adverse outcome. This emphasises the need for skilled health care workers at every delivery and for deliveries to take place in health facilities.
A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10\^6 cells/kg with a maximum dose of 10 x 10\^7 cells/kg.
Ephrin-B-EphB signaling can promote pain through ligand-receptor interactions between peripheral cells, like immune cells expressing ephrin-Bs, and EphB receptors expressed by DRG neurons. Previous studies have shown increased ephrin-B2 expression in peripheral tissues like synovium of rheumatoid and osteoarthritis patients, indicating the clinical significance of this signaling. The primary goal of this study was to understand how ephrin-B2 acts on mouse and human DRG neurons, which express EphB receptors, to promote pain and nociceptor plasticity. We hypothesized that ephrin-B2 would promote nociceptor plasticity and hyperalgesic priming through MNK-eIF4E signaling, a critical mechanism for nociceptive plasticity induced by growth factors, cytokines and nerve injury. Both male and female mice developed dose-dependent mechanical hypersensitivity in response to ephrin-B2, and both sexes showed hyperalgesic priming when challenged with PGE2 injection either to the paw or the cranial dura. Acute nociceptive behaviors and hyperalgesic priming were blocked in mice lacking MNK1 (Mknk1 knockout mice) and by eFT508, a specific MNK inhibitor. Sensory neuron-specific knockout of EphB2 using Pirt-Cre demonstrated that ephrin-B2 actions require this receptor. In Ca2+-imaging experiments on cultured DRG neurons, ephrin-B2 treatment enhanced Ca2+ transients in response to PGE2 and these effects were absent in DRG neurons from MNK1-/- and EphB2-PirtCre mice. In experiments on human DRG neurons, ephrin-B2 increased eIF4E phosphorylation and enhanced Ca2+ responses to PGE2 treatment, both blocked by eFT508. We conclude that ephrin-B2 acts directly on mouse and human sensory neurons to induce nociceptor plasticity via MNK-eIF4E signaling, offering new insight into how ephrin-B signaling promotes pain.
The present disclosure relates to a method and system for diagnosing coronavirus disease COVID-19 using artificial intelligence. Embodiments of the present disclosure provide methods and systems for detecting COVID-19 from images of a patient's lungs. The exemplary system may include a communication interface configured to receive a lung image of a lung of a patient acquired by an image acquisition device. The system may further include at least one processor configured to determine a region of interest including the lung from the lung image, and apply a codv-19 detection network to the region of interest to determine a condition of the lung. The COVID-19 detection network is a multi-class classification learning network that labels regions of interest as one of COVID-19, non-COVID-19 pneumonia, non-pneumonia abnormalities, or normality. The at least one processor is further configured to provide a diagnostic output based on the determined condition of the lung.
Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
The invention discloses a sodium alginate/starch-based enteric hollow capsule, which comprises a capsule body. The capsule body comprises the following raw materials in weight percentage: 15-30% of sodium alginate tech grade, 60-75% of starch, 3-10% of gelata, 6-15 parts of plasticizer, and 9.95-11.5% of water. According to the technical scheme of the hollow capsules of the invention, the hollow capsule thoroughly get rids of the dependence on animal-source raw materials. According to the enteric type hollow capsule preparation method, capsule embryoids are prevented from being subjected to enteric-coating or calcification for a second time during the preparation process. In this way, enteric capsule embryoids are prepared through the one-step glue dipping process, so that the production process of enteric hollow capsules is simplified. The requirements of existing hollow capsule production lines can be met, and no extra special production line is required. As a result, the production cost of products is greatly lowered. Enteric hollow capsules prepared through the above method are low in cost of raw materials. When the enteric hollow capsules are in a stomach of 0.9-1.5 in pH value for 2 hours, the enteric hollow capsules do not crack down or disintegrate. However, when the enteric hollow capsules are in a stomach of 6.8-8.2 in pH value, the enteric hollow capsules disintegrate completely within 30 minutes.
PROBLEM TO BE SOLVED: To obtain an aerosol having properties not needing the emulsifying operation in production, when sprayed the sprayed material coagulates like a sherbet manifesting continuous cooling effect, by formulating a liquid gas with a combination of specific alcohol. SOLUTION: The aerosol is consisting of a stock solution comprising (0.3-65wt.%) of a 1-3C lower alcohol, (0.005-14wt.%) of a higher alcohol having or more carbons and formulated liquid gas of (30-95wt.%). Ethanol is preferred as lower alcohol. Stearyl alcohol and cetyl alcohol are preferred as higher alcohol. This aerosol is produced by dissolving the lower alcohol and higher alcohol into a homogeneous system, the stock solution containing other ingredient not disturbing the homogeneous system, if necessary, is charged into the aerosol container with the liquid gas. On the point of duration of the cooling effect, an adequate amount of water (20-60wt.% of the stock solution) is preferably formulated as the ingredient not disturbing the homogeneous system.
The present invention relates to Bombina maxima antimicrobial peptide, a preparation method thereof and genes thereof, which belongs to the technical field of biomedicine. The antimicrobial peptide is a single-chain polypeptide obtained by separating the skin secretion of Bombina maxima which are amphibian animals in China. The molecular weight is 2840, the isoelectric point is 983, and a complete polypeptide amino acid sequence is in a primary structure: NH2-SIGAKILGGVKTFFKGALKELASTYLQ-NH2. The preparation method comprises the steps: the skin secretion of the Bombina maxima is collected; after the skin secretion is centrifuged for removing deposits and is frozen and dried, the skin secretion is treated by the steps of ion exchange and chromatographic separation and purification of a high-pressure liquid-phase reversed-phase column to obtain the antimicrobial peptide. The genes for coding antimicrobial peptide are formed from 663 nucleotides, wherein the genes for coding mature antimicrobial peptide are from the 165th nucleotide to the 245th nucleotide. The antimicrobial peptide has the function of broad-spectrum and obvious growth inhibition of bacteria and fungus, and the genes of the antimicrobial peptide are applied to the preparation of the antimicrobial peptide for gene engineering.
Notch signaling is involved in the prevention of cell differentiation and cell fate in various organs, including the lungs. We aimed to determine the transcriptomic and protein expression of Notch receptors, their ligands, and related transcription factors in stable COPD. The expression and localization of Notch receptors, their ligands, and related transcription factors were measured in bronchial biopsies of individuals with stable mild/moderate (MCOPD) (n = 18) or severe/very severe (SCOPD) (n = 16) COPD, control smokers (CSs) (n = 13), and control nonsmokers (CNSs) (n = 11), and in the lung parenchyma of those with MCOPD (n = 13), CSs (n = 10), and CNSs (n = 10) using immunohistochemistry, ELISA tests, and transcriptome analyses. In the bronchial biopsies, Notch4 and HES7 significantly increased in the lamina propria of those with SCOPD compared to those with MCOPD, CSs, and CNSs. In the peripheral lung bronchiolar epithelium, Notch1 significantly increased in those with MCOPD and CSs compared to CNSs. ELISA tests of lung parenchyma homogenates showed significantly increased Notch2 in those with MCOPD compared to CSs and CNSs. Transcriptomic data in lung parenchyma showed increased DLL4 and HES1 mRNA levels in those with MCOPD and CSs compared to CNSs. These data show the increased expression of the Notch pathway in the lungs of those with stable COPD. These alterations may play a role in impairing the regenerative-reparative responses of diseased bronchioles and lung parenchyma.